With 0.6 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.48 million shares. During the session, the Drug Manufacturers – Specialty & Generic company that operates in wider Healthcare sector, reached to the highest price of $27.0399 whereas the lowest price it dropped to was $25.77. The 52-week range on PCRX shows that it touched its highest point at $48.60 and its lowest point at $25.93 during that stretch. It currently has a 1-year price target of $45.30. Beta for the stock currently stands at 0.76.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of PCRX was down-trending over the past week, with a drop of -6.85%, but this was down by -9.33% over a month. Three-month performance dropped to -17.67% while six-month performance fell -9.76%. The stock lost -37.12% in the past year, while it has lost -21.37% so far this year. A look at the trailing 12-month EPS for PCRX yields 0.78 with Next year EPS estimates of 3.56. For the next quarter, that number is 0.63. This implies an EPS growth rate of -1.00% for this year and 27.84% for next year.
Float and Shares Shorts:
At present, 46.48 million PCRX shares are outstanding with a float of 45.17 million shares on hand for trading. On 2024-03-28, short shares totaled 3.74 million, which was 8.0299996 higher than short shares on 1709164800. In addition to Mr. Charles A. Reinhart III, CPA, M.B.A. as the firm’s Chief Financial Officer, Mr. Daryl Gaugler serves as its Chief Operating Officer.
Institutional Ownership:
Through their ownership of 1.08082 of PCRX’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2023-12-31, PCRX reported revenue of $181244000.0 and operating income of $33966000.0. The EBITDA in the recently reported quarter was $55706000.0 and diluted EPS was $nan.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for PCRX since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential.
Dividends & Yield:
In terms of dividends, PCRX has a current ratio of $––, which is $–– over the trailing 12-months, while a dividend of $–– is likely to be paid on average over the next five years. Dividend yield is another indicator that appeals to many investors, and PCRX currently yields $0.00. In the past year, PCRX’s dividend yield has been $0.00, but when looking at the stock over the past five years, its yield has been $–. Accordingly, PCRX has a current buyback yield of $–. This was $– for the TTM, and it was $– for the past five years.
